Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.62 |
| ▸ | FABP1 | P07148 | 5/20 | 0.56 |
| ▸ | FABP4 | P15090 | 1/20 | 0.54 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.54 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25515551 | 0.99 | NR1H4 (0.61) | NR1H4FABP1FABP4GPBAR1HSD17B13 | |
| SCHEMBL21703707 | 0.98 | NR1H4 (0.62) | NR1H4FABP1FABP4GPBAR1HSD17B13 | |
| SCHEMBL20859126 | 0.92 | NR1H4 (0.60) | NR1H4FABP1FABP4GPBAR1HSD17B13 | |
| SCHEMBL1097117 | 0.90 | NR1H4 (0.56) | NR1H4FABP1FABP4GPBAR1HSD17B13 | |
| SCHEMBL1095590 | 0.90 | NR1H4 (0.59) | NR1H4FABP1FABP4GPBAR1HSD17B13 | |
| SCHEMBL21244299 | 0.90 | NR1H4 (0.59) | NR1H4FABP1FABP4GPBAR1HSD17B13 | |
| SCHEMBL21244300 | 0.90 | NR1H4 (0.59) | NR1H4FABP1FABP4GPBAR1HSD17B13 | |
| SCHEMBL20859080 | 0.90 | NR1H4 (0.62) | NR1H4FABP1FABP4GPBAR1HSD17B13 | |
| SCHEMBL17856157 | 0.90 | NR1H4 (0.62) | NR1H4FABP1FABP4GPBAR1HSD17B13 | |
| Hydrochloric Acid SCHEMBL1096131 | 0.89 | NR1H4 (0.55) | NR1H4FABP1FABP4GPBAR1HSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829486-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACUETICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| WO-2019160813-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20190248777-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248777-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, SLC10A1, FXR1 | NR1H4 1/4885FABP1 24/4885FABP4 415/4885 |
| US-10829486-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, SLC10A1, FXR1 | NR1H4 1/4885FABP1 24/4885FABP4 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.